Johnson & Johnson, Apple ink collab for AFib study

Johnson & Johnson‘s (NYSE:JNJ) Janssen and Apple (NSDQ:AAPL) said today that the two companies inked a deal to study if an app from J&J in combination with the Apple Watch’s ECG app and irregular rhythm notifications can improve outcomes for people living with atrial fibrillation.
The study is slated to measure the impact of the Apple Watch on the early detection and diagnosis of AFib, as well as the efficacy of a medication adherence program.
Get the full story at our sister site, Drug Delivery Business News.
The post Johnson & Johnson, Apple ink collab for AFib study appeared first on MassDevice.

Source: Mass Device - January 17, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Business/Financial News Cardiovascular Drug-Device Combinations Featured mHealth (Mobile Health) Pharmaceuticals Wall Street Beat Apple Janssen Pharmaceuticals johnsonandjohnson Source Type: news